Recent advances in the treatment of non-small cell lung cancer with MET inhibitors
Recently, research into the oncogenic driver genes associated with non-small cell lung cancer (NSCLC) has advanced significantly, leading to the development and clinical application of an increasing number of approved therapeutic agents. Among these, small molecule inhibitors that target mesenchymal...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Chemistry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fchem.2024.1501844/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850107807727091712 |
|---|---|
| author | Dongna Zhang Wenying Zhang He Liu Pan Liu Chunxin Li Yangyang Liu Jicheng Han Guangze Zhu |
| author_facet | Dongna Zhang Wenying Zhang He Liu Pan Liu Chunxin Li Yangyang Liu Jicheng Han Guangze Zhu |
| author_sort | Dongna Zhang |
| collection | DOAJ |
| description | Recently, research into the oncogenic driver genes associated with non-small cell lung cancer (NSCLC) has advanced significantly, leading to the development and clinical application of an increasing number of approved therapeutic agents. Among these, small molecule inhibitors that target mesenchymal-epithelial transition (MET) have demonstrated successful application in clinical settings. Currently, three categories of small molecule MET inhibitors, characterized by distinct binding patterns to the MET kinase region, have been developed: types Ia/Ib, II, and III. This review thoroughly examines MET’s structure and its crucial role in NSCLC initiation and progression, explores discovery strategies for MET inhibitors, and discusses advancements in understanding resistance mechanisms. These insights are anticipated to enhance the development of a new generation of MET inhibitors characterized by high efficiency, selectivity, and low toxicity, thereby offering additional therapeutic alternatives for patients diagnosed with NSCLC. |
| format | Article |
| id | doaj-art-ff7047a5000b43daa5f64cdb9454c6fb |
| institution | OA Journals |
| issn | 2296-2646 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Chemistry |
| spelling | doaj-art-ff7047a5000b43daa5f64cdb9454c6fb2025-08-20T02:38:30ZengFrontiers Media S.A.Frontiers in Chemistry2296-26462024-12-011210.3389/fchem.2024.15018441501844Recent advances in the treatment of non-small cell lung cancer with MET inhibitorsDongna Zhang0Wenying Zhang1He Liu2Pan Liu3Chunxin Li4Yangyang Liu5Jicheng Han6Guangze Zhu7Department of Clinical Laboratory Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, ChinaDepartment of Clinical Laboratory Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, ChinaDepartment of Clinical Laboratory Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, ChinaDepartment of Clinical Laboratory Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, ChinaDepartment of Clinical Laboratory Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, ChinaDepartment of Clinical Laboratory Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, ChinaKey Laboratory of Jilin Province for Traditional Chinese Medicine Prevention and Treatment of Infectious Diseases, College of integrative medicine, Changchun University of Chinese Medicine, Changchun, ChinaDepartment of Clinical Laboratory Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, ChinaRecently, research into the oncogenic driver genes associated with non-small cell lung cancer (NSCLC) has advanced significantly, leading to the development and clinical application of an increasing number of approved therapeutic agents. Among these, small molecule inhibitors that target mesenchymal-epithelial transition (MET) have demonstrated successful application in clinical settings. Currently, three categories of small molecule MET inhibitors, characterized by distinct binding patterns to the MET kinase region, have been developed: types Ia/Ib, II, and III. This review thoroughly examines MET’s structure and its crucial role in NSCLC initiation and progression, explores discovery strategies for MET inhibitors, and discusses advancements in understanding resistance mechanisms. These insights are anticipated to enhance the development of a new generation of MET inhibitors characterized by high efficiency, selectivity, and low toxicity, thereby offering additional therapeutic alternatives for patients diagnosed with NSCLC.https://www.frontiersin.org/articles/10.3389/fchem.2024.1501844/fullNSCLCMET inhibitorsdrug discoverystructure-activity relationshipstargeted therapy |
| spellingShingle | Dongna Zhang Wenying Zhang He Liu Pan Liu Chunxin Li Yangyang Liu Jicheng Han Guangze Zhu Recent advances in the treatment of non-small cell lung cancer with MET inhibitors Frontiers in Chemistry NSCLC MET inhibitors drug discovery structure-activity relationships targeted therapy |
| title | Recent advances in the treatment of non-small cell lung cancer with MET inhibitors |
| title_full | Recent advances in the treatment of non-small cell lung cancer with MET inhibitors |
| title_fullStr | Recent advances in the treatment of non-small cell lung cancer with MET inhibitors |
| title_full_unstemmed | Recent advances in the treatment of non-small cell lung cancer with MET inhibitors |
| title_short | Recent advances in the treatment of non-small cell lung cancer with MET inhibitors |
| title_sort | recent advances in the treatment of non small cell lung cancer with met inhibitors |
| topic | NSCLC MET inhibitors drug discovery structure-activity relationships targeted therapy |
| url | https://www.frontiersin.org/articles/10.3389/fchem.2024.1501844/full |
| work_keys_str_mv | AT dongnazhang recentadvancesinthetreatmentofnonsmallcelllungcancerwithmetinhibitors AT wenyingzhang recentadvancesinthetreatmentofnonsmallcelllungcancerwithmetinhibitors AT heliu recentadvancesinthetreatmentofnonsmallcelllungcancerwithmetinhibitors AT panliu recentadvancesinthetreatmentofnonsmallcelllungcancerwithmetinhibitors AT chunxinli recentadvancesinthetreatmentofnonsmallcelllungcancerwithmetinhibitors AT yangyangliu recentadvancesinthetreatmentofnonsmallcelllungcancerwithmetinhibitors AT jichenghan recentadvancesinthetreatmentofnonsmallcelllungcancerwithmetinhibitors AT guangzezhu recentadvancesinthetreatmentofnonsmallcelllungcancerwithmetinhibitors |